Reslizumab for Poorly Controlled, Eosinophilic Asthma

Abstract

Patients receiving reslizumab showed significantly greater reductions in sputum eosinophils, improvements in airway function, and a trend toward greater asthma control than those receiving placebo. Reslizumab was generally well tolerated.